Many people diagnosed with pulmonary hypertension do live for years and even decades, though survival depends heavily on the type of pulmonary hypertension, how early it is caught, and how aggressively it is treated. Before modern therapies became available, the median survival for pulmonary arterial hypertension was under three years. Today, five-year survival rates for certain forms exceed 85 percent, and even the most severe cases respond better to treatment than they did a generation ago. The picture is more complicated than a single number can capture, and the specifics matter enormously.
Why the Type of Pulmonary Hypertension Changes Everything
Pulmonary hypertension is not one disease. It is classified into five groups based on what is driving the elevated pressure in the lung arteries. Group 1, called pulmonary arterial hypertension (PAH), involves disease of the small pulmonary arteries themselves. Group 2 is caused by left-sided heart disease. Group 3 is linked to chronic lung conditions. Group 4, known as chronic thromboembolic pulmonary hypertension (CTEPH), results from blood clots that never fully dissolved. Group 5 is a catch-all for miscellaneous causes.
A large population-based study in Ontario found that overall five-year mortality across all groups was about 62 percent, but this headline number is misleading if you have a specific subtype. Mortality was highest in Groups 2 and 3, which tend to occur in older adults with established heart or lung disease, and lowest in Group 1. Children with Group 1 PAH fared significantly better, with five-year mortality around 21 percent.1PubMed Central. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada These numbers reflect all comers in a real-world registry, including people diagnosed late, those with severe comorbidities, and those who may not have received optimal therapy. They are not destiny for any individual patient.
How Treatment Has Reshaped Survival in PAH
The story of PAH survival is largely a story of better drugs used more aggressively. A European center tracking patients over 15 years reported a median transplant-free survival of about six years overall, with one-year survival at 88 percent and five-year survival at 57 percent.2PubMed Central. The evolution of survival of pulmonary arterial hypertension over 15 years Those numbers pool patients from different treatment eras and severity levels. What matters more is what happens when people receive the best available therapy from the start.
The biggest shift in recent years has been toward starting patients on multiple drugs at once rather than adding them one at a time. A study of over 1,100 intermediate-risk PAH patients found that those started on triple combination therapy had a five-year survival rate of 91 percent, compared with 61 percent for those on one or two drugs. After adjusting for other risk factors, triple therapy was linked to more than a 70 percent lower risk of death.3PubMed Central. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension Even at the ten-year mark, survival with triple therapy remained around 85 percent in propensity-matched comparisons with dual therapy, which sat near 65 percent. Data from the Pulmonary Hypertension Association Registry confirmed that initial combination therapy cut the one-year risk of death by more than half compared with starting on a single drug.4PubMed Central. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
The practical takeaway is that PAH patients treated at experienced centers, where aggressive upfront combination therapy is standard, tend to do far better than the population-level statistics suggest. If your doctor has started you on only one medication for PAH, it is worth asking whether combination therapy might be appropriate.
Sotatercept and the Newest Wave of Treatment
Until recently, all approved PAH drugs worked by relaxing blood vessels. They did not address the underlying remodeling of the artery walls that causes the disease to progress. Sotatercept, approved in 2024, works differently: it targets a signaling pathway involved in the abnormal cell growth that thickens and stiffens pulmonary arteries.
In a phase 3 trial, patients who added sotatercept to their existing PAH therapy improved their six-minute walk distance by roughly 40 meters more than those on placebo, along with improvements across multiple secondary measures of disease severity.5PubMed. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension An earlier trial had shown meaningful drops in pulmonary vascular resistance, the key measure of how hard the right side of the heart has to work.6PubMed. Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Perhaps most striking, a trial focused specifically on high-risk PAH patients found that sotatercept cut the rate of disease worsening or death events dramatically. Primary endpoint events occurred in about 17 percent of the sotatercept group versus roughly 55 percent of the placebo group, and the trial was stopped early because the benefit was so clear.7PubMed. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death Long-term survival data from sotatercept trials are still maturing, but the drug represents the first genuinely new mechanism of action for PAH in decades, and the early results suggest it could meaningfully extend life for people whose disease was not well controlled on older therapies.
CTEPH Can Sometimes Be Cured
Group 4 pulmonary hypertension, caused by chronic blood clots in the lung arteries, is unique because it is potentially curable. The primary treatment is pulmonary endarterectomy (PEA), a complex surgery where surgeons physically remove the organized clot material from the arteries. An international registry found that three-year survival after PEA was 94 percent, compared with 71 percent for patients who did not undergo any mechanical intervention.8PubMed Central. Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy Operated patients consistently show better long-term prognosis than those managed with medication alone.9PubMed. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry
A Swedish study looking at very long follow-up found that for patients who survived the surgery and early recovery period, life expectancy came close to that of the general population. The 15-year relative survival, conditional on making it through the first 30 days, was 83 percent.10PubMed Central. Life expectancy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Swedish single-center study That is about as close to “cured” as any form of pulmonary hypertension gets.
For patients with CTEPH who cannot undergo surgery, balloon pulmonary angioplasty (BPA) has emerged as an alternative. A multicenter study reported five-year survival of 95 percent with BPA, compared with about 69 percent without the procedure, with long-term outcomes comparable to surgical endarterectomy.11JACC: Asia. Long-Term Survival of Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study The key point for anyone with CTEPH is that evaluation at a specialized center is essential, because missing the opportunity for PEA or BPA means missing a chance at near-normal life expectancy.
Lung Transplant as a Last Resort
For patients with severe PAH that does not respond adequately to medical therapy, lung transplantation remains an option. It is not a first-line treatment and carries significant risks. A study of transplant outcomes for idiopathic PAH found that survival improved substantially over time as surgical techniques advanced, with the more recent cohort achieving one-year survival of 86 percent and ten-year survival of 66 percent, compared with 58 percent and 27 percent in the earlier era.12The Annals of Thoracic Surgery. Long-Term Outcome of Lung and Heart-Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension Transplant is a realistic path for a subset of patients, but the availability of donor organs, the complexity of post-transplant care, and the risks of rejection mean it is reserved for those who have exhausted other options.
What Predicts Who Does Well and Who Does Not
Survival in PAH is not random. A large U.S. registry identified a range of factors that independently predict worse outcomes. Pulmonary vascular resistance above a certain threshold, more advanced functional impairment (struggling with daily activities or being symptomatic at rest), being male and over 60, having PAH associated with portal hypertension or connective tissue disease, kidney dysfunction, and the presence of fluid around the heart all predicted higher mortality.13PubMed. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
How well the right side of the heart adapts to the increased workload turns out to be one of the most important determinants of prognosis. When pulmonary artery pressure rises, the right ventricle initially compensates by growing thicker and pumping harder. Some patients maintain this compensated state for years. Others develop right ventricular failure, where the heart muscle dilates and weakens. The difference between these two trajectories has an outsized influence on functional capacity and survival.14PubMed Central. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure This is why regular monitoring of heart function, not just pulmonary artery pressure, is a central part of PH management.
Kidney function also matters independently. Impaired kidney function is common in PAH patients and predicts worse survival even after accounting for other risk factors.15PubMed Central. Kidney dysfunction in patients with pulmonary arterial hypertension
The Diagnostic Delay Problem
One of the most frustrating aspects of pulmonary hypertension is how long it takes to get diagnosed. The early symptoms, such as breathlessness during exertion, fatigue, and lightheadedness, overlap with dozens of more common conditions. As a result, the median time from first symptoms to a confirmed diagnosis of PAH has been stuck at over two years for decades, going all the way back to the 1980s NIH registry.16PubMed Central. Assessing the Impact of Time to Diagnosis and Treatment for Patients With Pulmonary Arterial Hypertension An Australian and New Zealand registry found a similar median diagnostic interval of about 1.2 years, and that longer delays were associated with worse five-year survival.17PubMed. Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry
This matters for the longevity question because all of those impressive treatment survival numbers come from people whose disease was recognized and treated. Every month of delay is a month of uncontrolled pressure damage to the pulmonary arteries and right heart. If you have unexplained shortness of breath that is gradually worsening, especially if you are young, female, or have a connective tissue disease, pushing for a thorough cardiac evaluation rather than accepting “you’re just out of shape” can meaningfully change your long-term outlook.
Exercise, Oxygen, and Day-to-Day Management
For years, patients with pulmonary hypertension were told to avoid exercise. That advice has reversed. A systematic review and meta-analysis found that supervised exercise training improved six-minute walk distance by about 53 meters, improved peak oxygen uptake, lowered resting pulmonary artery pressure, and improved quality-of-life scores, all without serious adverse events.18PubMed. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis A large European randomized trial confirmed that standardized exercise training was feasible and safe in both PAH and CTEPH patients, improving functional class and mental health.19European Heart Journal. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial
The emphasis is on supervised, structured exercise rather than just “go for a jog.” Pulmonary rehabilitation programs specifically designed for PH patients combine aerobic training, breathing exercises, and education in a monitored setting.20PubMed Central. Pulmonary rehabilitation and exercise in pulmonary arterial hypertension: An underutilized intervention These programs remain underused, partly because many doctors still default to the old “take it easy” advice and partly because access is limited.
Supplemental oxygen is another piece of the puzzle. A systematic review found that short-term oxygen therapy improved pulmonary artery pressure and exercise performance, with growing evidence that long-term use may benefit exercise capacity and possibly survival in selected patients.21PubMed. Oxygen Therapy in Pulmonary Vascular Disease: A Systematic Review, Meta-Analysis, and Comment Not every PH patient needs oxygen, but those with significant drops in blood oxygen levels during activity or sleep often see tangible benefits.
Children With Pulmonary Hypertension
PAH in children is uncommon but not rare, and its prevalence is growing as more cases are recognized and children with congenital heart disease survive longer into childhood.22PubMed Central. Pulmonary Hypertension in Children The prognosis for pediatric PAH sits somewhere between encouraging and sobering. A global registry reported that about 72 percent of children with newly diagnosed PAH survived five years without death or transplant.23European Heart Journal – Quality of Care and Clinical Outcomes. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry Data from the U.S. REVEAL registry found five-year survival from diagnosis of about 74 percent for the overall pediatric cohort, with no significant difference between idiopathic PAH and PAH linked to congenital heart disease.24PubMed. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management
Older age at diagnosis was the strongest predictor of worse survival in children, which is a counterintuitive finding. Younger children may be diagnosed earlier in the disease course because symptoms are more noticeable to parents and pediatricians, whereas older children may be dismissed as merely unfit. The principles that apply to adults also hold for children: earlier diagnosis and aggressive treatment at specialized centers give the best outcomes.
Pregnancy and Pulmonary Hypertension
Pregnancy remains one of the highest-risk situations for women with PAH, and all major guidelines continue to advise against it. The reason is physiological: pregnancy increases blood volume by roughly 50 percent and cardiac output by a similar margin, placing enormous additional stress on an already strained right ventricle. A study using the U.S. National Inpatient Sample found that women with pulmonary hypertension had major cardiac events during pregnancy at a rate of roughly 25 percent, compared with 0.4 percent in women without PH or heart disease. They also faced substantially higher rates of eclampsia, preterm delivery, and fetal death.25PubMed Central. Pulmonary Hypertension and Pregnancy Outcomes: Insights From the National Inpatient Sample
Maternal mortality has improved somewhat with modern care, but it remains high enough that pregnancy is classified as a high-risk event in PAH.26European Respiratory Review. Pregnancy in pulmonary arterial hypertension Women with well-controlled disease who choose to proceed with pregnancy should be managed exclusively at expert centers with multidisciplinary teams. Effective contraception is considered a core part of PAH management for women of childbearing age.
Mental Health as Part of Living Longer
Living with a chronic, life-threatening condition takes a psychological toll that affects quality of life and may influence how well patients manage their disease. Depression is remarkably common in PH patients, with studies reporting rates of moderate-to-severe depressive symptoms ranging from about 18 percent to over 50 percent depending on disease severity and the measure used.27PubMed Central. Anxiety and depression in patients with pulmonary hypertension: impact and management challenges Anxiety and panic disorders are similarly prevalent. A mixed-methods study found that about 45 percent of PH patients reported at least mild depressive symptoms, with PAH patients particularly affected, and that rates climbed sharply in those with more functional limitation or full-time oxygen use.28BMJ Open. Depression, anxiety and psychological distress in patients with pulmonary hypertension: a mixed-methods study
Depression is not just an unpleasant side effect of illness. In heart failure populations, depression is associated with worse medication adherence, less physical activity, and higher mortality. The same dynamics likely apply in PH. Screening for depression and anxiety should be a routine part of PH care, and treatment, whether through therapy, medication, or peer support, is part of a long-term survival strategy, not a luxury.
Socioeconomic Factors and Access to Care
PAH therapies are expensive, and access to specialized centers is uneven. A U.S. study found that patients in the lowest socioeconomic bracket had three-year survival of about 50 percent, compared with 86 percent in the highest bracket. Even after adjusting for clinical features and treatment type, the lowest-income patients had roughly triple the risk of death.29PubMed Central. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension This gap is enormous and likely reflects barriers to accessing specialty care, affording medications, maintaining consistent follow-up, and getting timely diagnoses.
Interestingly, a study from a publicly funded healthcare system found no survival difference across socioeconomic groups, suggesting that when financial barriers to care are removed, the disparity largely disappears.30PubMed Central. Socioeconomic status and survival in patients with pulmonary hypertension For patients navigating the U.S. healthcare system, pharmaceutical patient assistance programs, specialty pharmacy support, and Pulmonary Hypertension Association resources can help bridge some of these gaps.
Implantable Monitors and Proactive Management
One challenge in managing PH is that symptoms can be deceptive. Patients sometimes feel stable while pressures are creeping upward, and by the time symptoms worsen, the heart has already taken a hit. Implantable hemodynamic sensors, originally developed for heart failure, are being used in PAH to provide real-time pulmonary artery pressure readings. Early experience with the CardioMEMS system showed that it could safely monitor PAH patients and detect changes in pressure and cardiac output within the first month after implant, leading to earlier medication adjustments and improvements in functional status and quality of life within a year.31PubMed Central. Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor
This technology is still relatively new in PH, but it represents a broader shift toward proactive rather than reactive management. Instead of waiting for symptoms to deteriorate before changing therapy, clinicians can intervene at the first sign of pressure creeping up. Over time, this approach could translate into fewer hospitalizations and longer stretches of stable disease, though large-scale survival studies specific to PH are still needed.